Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
| Revenue (TTM) | $770.20M |
| Gross Profit (TTM) | $380.40M |
| EBITDA | $232.40M |
| Operating Margin | 28.30% |
| Return on Equity | -40.30% |
| Return on Assets | 6.93% |
| Revenue/Share (TTM) | $14.76 |
| Book Value | $6.66 |
| Price-to-Book | 0.69 |
| Price-to-Sales (TTM) | 0.30 |
| EV/Revenue | 0.913 |
| EV/EBITDA | 5.24 |
| Quarterly Earnings Growth (YoY) | -93.80% |
| Quarterly Revenue Growth (YoY) | 66.30% |
| Shares Outstanding | $51.27M |
| Float | $49.06M |
| % Insiders | 4.26% |
| % Institutions | 90.19% |
Volatility is currently expanding
Emergent BioSolutions reported approximately $97 million in adjusted EBITDA for the quarter. The same period included a $191.3 million non-cash NARCAN impairment.
Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations. Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations.
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026.
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026.
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month.
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EBS and any ticker you trade — then tracks every position and per-strategy win rate.
